Tertiary lymphoid structures (TLSs)—organized clusters of immune cells within tumors—are critical for effective cancer immunotherapy, according to a study published in Science. Researchers at the Icahn School of Medicine at Mount Sinai identified type 1 conventional dendritic cells (cDC1s) as the essential architects that form and maintain these structures, suggesting a new path for improving patient responses to checkpoint inhibitors.
The Role of cDC1s in Tumor Immunity
While immune cells often infiltrate tumors, they are not always organized into functional units. TLSs act as localized sites for antigen presentation and T-cell activation, mimicking the function of lymph nodes. According to lead author Raphael Mattiuz, PhD, cDC1s serve as the primary organizers of these hubs, bringing diverse immune cells together to sustain an anti-cancer response.
The research team utilized multiplex imaging and spatial gene-expression analysis on tumor samples from patients with lung, kidney, colorectal, ovarian, and liver cancers. They observed that mature dendritic cells naturally accumulate within these TLSs. By using a mouse model of non-small cell lung cancer, the researchers confirmed that cDC1s are required both for the initial establishment of TLSs and for their long-term maintenance.
Did you know? Unlike standard lymph nodes, TLSs develop directly within chronically inflamed tissues, such as the tumor microenvironment, providing a frontline base for the immune system to combat malignant cells.
Beyond T-Cell Priming: A Two-Stage Process
The study reveals that cDC1s function in a two-stage capacity. Early in tumor development, these cells rely on IFNγ-driven maturation to recruit primed T cells into the tumor. As the tumor progresses, the biology shifts. cDC1s become retained within stromal hubs enriched in CCR7 ligands, acting as tissue-resident coordinators rather than simple antigen couriers.
Mechanistic evidence shows that depleting cDC1s after TLSs have formed causes the structures to disintegrate. Furthermore, the functional integrity of these TLSs—including B-cell maturation and the production of tumor-specific IgG—depends on the antigen-presenting capabilities of cDC1s. When MHC class I and II were genetically ablated on these cells, the researchers observed a failure in TLS maintenance and T-cell exhaustion.
Future Trends in Immunotherapy Design
Current checkpoint inhibitors do not work for every patient, often because the tumor lacks the necessary spatial organization to sustain a productive immune response. Future therapeutic strategies may focus on “spatial engineering” of the tumor microenvironment. Potential approaches include:
- cDC1 Enrichment: Increasing the abundance of these cells to jump-start TLS formation.
- Targeted Retention: Enhancing the recruitment or retention of cDC1s within stromal hubs to prevent TLS decay.
- Combination Therapies: Pairing cDC1-activating agents with existing checkpoint inhibitors, vaccines, or radiotherapy to maximize the durability of the immune response.
Pathologists may also change how they evaluate tumors. Rather than viewing TLSs as a binary “present or absent” feature, future diagnostic assays could assess the maturity and cellular composition of these structures to better predict which patients will respond to specific treatments.
Frequently Asked Questions
What are Tertiary Lymphoid Structures (TLSs)?
TLSs are organized clusters of immune cells that form within tumors and inflamed tissues, serving as local sites for immune coordination, including T-cell activation and antibody production.
Why are cDC1s important for cancer treatment?
According to the Icahn School of Medicine at Mount Sinai, cDC1s are the “organizers” of TLSs. Without them, the immune system may struggle to maintain the organized structure required for a durable response against cancer cells.
Can we use this to treat patients now?
Not yet. The study provides a mechanistic framework, but clinical interventions based on cDC1 activation have not been established. Future research will focus on whether these biological insights can be safely and effectively translated into human therapies.
Pro Tip: When reviewing pathology reports for clinical trials or experimental studies, look for mentions of “TLS quality” or “germinal center formation” rather than just the presence of immune aggregates.
How do you think spatial biology will reshape the future of oncology? Share your thoughts in the comments below or sign up for our newsletter to stay updated on the latest breakthroughs in tumor immunology.